Clinical Trials / Research Studies
Neurofibromatosis Other

Other Solid Tumors Research Studies

< Back to Pediatric Cancer Research Studies Page

Solid Tumors Neurofibromatosis Other

ADVL1721: A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma

  • Ages: 6 months to 21 Years

BRIEF SUMMARY: This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
 PRIMARY OUTCOME MEASURES: The maximum tolerated dose (MTD) [ ...More

NF110: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)

  • Ages: 6 Years and older

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 c ...More

Contact Us

Contact us.

To learn more about available clinical trials related to solid tumors, contact us at cancer@cchmc.org or 513-636-2799.

Related Studies